Tengion (Tengion) Total Current Liabilities : $59.55 Mil (As of Sep. 2014)

View and export this data going back to 2010. Start your Free Trial

What is Tengion Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Tengion's total current liabilities for the quarter that ended in Sep. 2014 was $59.55

Tengion Total Current Liabilities Historical Data

The historical data trend for Tengion's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Total Current Liabilities Chart

Tengion Annual Data

Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13

Total Current Liabilities

Get a 7-Day Free Trial 18.04 8.26 9.08 13.76 16.64

Tengion Quarterly Data

Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14

Total Current Liabilities Get a 7-Day Free Trial 29.43 16.64 39.31 50.14 59.55

Tengion Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Tengion's Total Current Liabilities for the fiscal year that ended in Dec. 2013 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 2.462 + 1.329

+ Other Current Liabilities + Current Deferred Liabilities

= 12.847 + 0

= 16.64

Tengion's Total Current Liabilities for the quarter that ended in Sep. 2014 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 2.127 + 0.68

+ Other Current Liabilities + Current Deferred Liabilities

= 56.742 + 0

= 59.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Tengion Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Tengion's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tengion (Tengion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Total Current Liabilities

Comparable Companies

VITIF HSTC NTRR TLOG NSPX ERGO OPLI GLAG FPMI ADYNF ENTB CAPS BTHE GOVX LCAR CTBO IMUC GNBT ICOTF TIKRF

Traded in Other Exchanges

N/A

Address

3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103

Website

http://www.tengion.com

Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.

Executives

John L Miclot director, officer: President and CEO 5005 OLD ORCHARD LANE, GIBSONIA PA 15044

Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

A Brian Davis officer: Chf. Fin. Offr, VP Fin. C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Medtronic Inc 10 percent owner 710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432

Johan Christenson 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51

Staffan Lindstrand 10 percent owner C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51

Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432

Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482

Mark Stejbach officer: VP and Chief Commercial Offcr C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Steven Nichtberger director, officer: President and CEO C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104

Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933

Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901

Oak Investment Partners Xi L P 10 percent owner 901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)
By gurufocus 10qk • 05-20-2010

Tengion Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Total Current Liabilities	Get a 7-Day Free Trial															29.43	16.64	39.31	50.14	59.55

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	2.462	+	1.329
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	12.847	+	0
	=	16.64

John L Miclot	director, officer: President and CEO	5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis	officer: Chf. Fin. Offr, VP Fin.	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc	10 percent owner	710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach	officer: VP and Chief Commercial Offcr	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger	director, officer: President and CEO	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P	10 percent owner	901 MAIN AVENUE, SUITE 600, NORWALK CT 06851